Aphria (NASDAQ:APHA) posted its quarterly earnings results on Wednesday. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.39), Briefing.com reports. The company had revenue of $160.50 million during the quarter, compared to the consensus estimate of $153.75 million. Aphria had a negative net margin of 18.30% and a negative return on equity of 2.23%. Aphria’s quarterly revenue was up 33.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.03) EPS.
Aphria stock opened at $12.42 on Friday. The company’s fifty day simple moving average is $7.62 and its 200-day simple moving average is $6.45. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.30 and a current ratio of 5.37. Aphria has a 12 month low of $1.95 and a 12 month high of $14.01.
Several research firms have issued reports on APHA. Canaccord Genuity raised Aphria from a “hold” rating to a “speculative buy” rating and upped their price target for the company from $11.00 to $17.50 in a report on Friday. Cantor Fitzgerald upped their price target on Aphria from $11.75 to $26.00 and gave the company an “overweight” rating in a report on Friday. BMO Capital Markets upped their price target on Aphria from $7.00 to $15.00 and gave the company a “market perform” rating in a report on Friday. CIBC upped their price target on Aphria from $12.50 to $18.00 and gave the company an “outperform” rating in a report on Friday. Finally, Zacks Investment Research downgraded shares of Aphria from a “hold” rating to a “sell” rating in a research note on Monday, December 28th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $14.23.
Aphria Inc cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands.
Featured Article: How to track put option volume
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.